Clinical trials: Temozolomide, completed
Glioblastoma
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
The purpose of this study is to test the the efficacy and safety of Anlotinib in combination with STUPP regimen for patients with newly diagnosed glioblastoma.
- Trial name
- NCT04119674
- Testing
- Drug is Anlotinib., Drug is Temozolomide Capsule., Radiotherapy was initiated 4 to 6 weeks postoperatively.
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zhejiang Cancer Hospital
Glioblastoma Multiforme, Primary Brain Tumor
Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status
The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS) <70 is unestablished.
- Trial name
- ATAG (NCT02898012)
- Testing
- Temozolomide, Bevacizumab
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354068
- Testing
- imatinib mesylate, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Glioblastoma Multiforme
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00262730
- Testing
- poly ICLC, temozolomide, radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme
BG & TMZ Therapy of Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01269424
- Testing
- MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanton Gerson MD
Melanoma
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Temozolomide (also known as TMZ) is a chemotherapy drug given by mouth. It is similar to DTIC, the only FDA-approved chemotherapy for melanoma, but because temozolomide is given by mouth, it can be given daily over a long period…
- Trial name
- NCT00591370
- Testing
- Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme
INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study
Glioblastoma multiforme (GBM) is a disease with an extremely poor prognosis. Despite surgery and radiochemotherapy, the tumors are likely to grow back very quickly.
- Trial name
- NCT02104882
- Testing
- Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Universitätsmedizin Mannheim
High Grade Glioma
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
This randomized, open-label, multicenter, 2-arm study will investigate the efficacy, safety, tolerability and pharmacokinetics of bevacizumab when added to postoperative radiotherapy with concomitant and adjuvant TMZ as compared…
- Trial name
- NCT01390948
- Testing
- Bevacizumab, Radiotherapy, Temozolomide (TMZ)
- Where
- 53 sites in Australia, Austria and 12 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006353
- Testing
- temozolomide, radiation therapy
- Where
- 16 sites in Canada
- Volunteers
- 575 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Primary CNS Lymphoma (PCNSL)
Treatment of Primary CNS Lymphoma ( FTD )
The purpose of this study is to evaluate the efficacy and safety of FTD regiment (fotemustine, temozolomide and dexamethasone ) for patients with primary CNS lymphoma.
- Trial name
- NCT05274139
- Testing
- HD-MTX-Ara-C regimen, FTD regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Ovarian Cancer, Testicular Germ Cell Tumor
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have metastatic…
- Trial name
- NCT00006043
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Melanoma
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00301067
- Testing
- Calcitriol, Temozolomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Melanoma
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma
Ocular melanoma, or cancer of the eye, is a rare form of cancer that can spread to the liver. A tumor in the liver, because of its size or location, sometimes cannot be removed with surgery.
- Trial name
- NCT00062933
- Testing
- Laparotomy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I trial is studying the side effects and best dose of temsirolimus when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00316849
- Testing
- pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Tumors, Malignant Tumors
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
Long term survival can now be achieved in 75% of cases of pediatric cancers. However, some types of tumors (ie CNS tumors) or advanced stages (metastatic sarcomas/neuroblastomas) cannot be cured by any treatment.
- Trial name
- NCT00412503
- Testing
- Topotecan, Temozolomide
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gastrointestinal Stromal Tumors, Sdh
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Funding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib.
- Conditions
- Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
- Trial name
- NCT03556384
- Testing
- Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adam Burgoyne, MD, PhD
Glioblastoma
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and…
- Trial name
- NCT00068952
- Testing
- Edotecarin, Temozolomide, Carmustine (BCNU)
- Where
- 52 sites in United States, Australia and 11 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Glioblastoma Multiforme
The Addition of Chloroquine to Chemoradiation for Glioblastoma
Patients with a glioblastoma (GBM) have a poor prognosis with a median survival of 14.6 months after maximal treatment with a resection and chemoradiation.
- Trial name
- CHLOROBRAIN (NCT02378532)
- Testing
- Chloroquine, Radiotherapy, Temozolomide
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Maastricht Radiation Oncology